BLTE Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.510

+59.38%

-0.633

+40.74%

-0.587

+17.33%

Estimates Revision

The market is revising No Change the revenue expectations for Belite Bio, Inc (BLTE) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 106.65%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+11.27%

In Past 3 Month

Stock Price

Go Up

+106.65%

In Past 3 Month

6 Analyst Rating

Wall Street analysts forecast BLTE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLTE is 167.50 USD with a low forecast of 85.00 USD and a high forecast of 200.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

85.00

Averages

167.50

High

200.00

Current: 0.000

Low

85.00

Averages

167.50

High

200.00

Morgan Stanley

Overweight

initiated

$191

2026-01-06

New

Reason

Morgan Stanley

Price Target

$191

2026-01-06

New

initiated

Overweight

Reason

Morgan Stanley initiated coverage of Belite Bio with an Overweight rating and $191 price target. The firm says its key opinion leader checks support a multi-billion dollar opportunity for tinlarebant in Stargardt disease type 1. Potential regulatory approval and commercial launch are catalysts to move shares higher over the next 12 months, the analyst tells investors in a research note.

Maxim

NULL -> Buy

maintain

$140 -> $200

2025-12-02

Reason

Maxim

Price Target

$140 -> $200

2025-12-02

maintain

NULL -> Buy

Reason

Maxim raised the firm's price target on Belite Bio to $200 from $140 and keeps a Buy rating on the shares after the company reported positive topline results from the Phase 3 DRAGON trial of tinlarebant in adolescent Stargardt disease.

Mizuho

Graig Suvannavejh

Neutral -> Outperform

upgrade

$194

2025-12-02

Reason

Mizuho

Graig Suvannavejh

Price Target

$194

2025-12-02

upgrade

Neutral -> Outperform

Reason

Mizuho analyst Graig Suvannavejh upgraded Belite Bio to Outperform from Neutral with a $194 price target.

Mizuho

Graig Suvannavejh

Neutral -> Outperform

upgrade

$105 -> $194

2025-12-02

Reason

Mizuho

Graig Suvannavejh

Price Target

$105 -> $194

2025-12-02

upgrade

Neutral -> Outperform

Reason

Mizuho analyst Graig Suvannavejh upgraded Belite Bio to Outperform from Neutral with a price target of $194, up from $105. The firm cites the positive Phase 3 data for tinlarebant in Stargardt disease for the upgrade. The data are "impressive" and better than Mizuho's expectations on both efficacy and safety, the analyst tells investors in a research note. The firm increased its probability of success assumptions for tinlarebant to 85% from 40%-60% prior. Mizuho sees the drug's U.S. launch pricing at $350,000 and moved up its risk-unadjusted tinlarebant sales estimate to $4.2B. It sees further upside in the shares post the data.

Cantor Fitzgerald

NULL -> Overweight

initiated

$154

2025-11-24

Reason

Cantor Fitzgerald

Price Target

$154

2025-11-24

initiated

NULL -> Overweight

Reason

Cantor Fitzgerald assumed coverage of Belite Bio with an Overweight rating and $154 price target. Belite is set to report Phase 3 data this quarter for tinlarebant in Stargardt disease, with the readout notable because the one-year futility analysis already achieved statistical significance, the FDA granted breakthrough designation based on that interim success, and multiple regulators, including in China and the U.K., have agreed to accept filings using the interim data, the analyst tells investors in a research note.

Mizuho

Neutral

initiated

$105

2025-11-20

Reason

Mizuho

Price Target

$105

2025-11-20

initiated

Neutral

Reason

Mizuho initiated coverage of Belite Bio with a Neutral rating and $105 price target. The firm views Belite as a "unique, one-product story," with tinlarebant in Phase 3 for Stargardt disease. While the firm project $4B in peak worldwide sales for tinlarebant, it finds handicapping the Phase 3 outcome challenging. Tinlarebant's existing data on efficacy, "while promising," are not "particularly robust," the analyst tells investors in a research note.

Valuation Metrics

The current forward P/E ratio for Belite Bio Inc (BLTE.O) is -69.35, compared to its 5-year average forward P/E of -35.75. For a more detailed relative valuation and DCF analysis to assess Belite Bio Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-35.75

Current PE

-69.35

Overvalued PE

-24.50

Undervalued PE

-46.99

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-6.86

Current EV/EBITDA

-156.71

Overvalued EV/EBITDA

21.82

Undervalued EV/EBITDA

-35.53

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

10.58

Current PS

0.00

Overvalued PS

55.09

Undervalued PS

-33.93

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

BLTE News & Events

Events Timeline

No data

News

4.0

01-06CNBC

Morgan Stanley Initiates Belite Bio at Overweight with $191 Price Target

2.0

2025-12-19NASDAQ.COM

The $100 Club - Did You Get in Early on the Triple-Digit Surge of ABVX, NUTX, BLTE…?

4.0

2025-12-06NASDAQ.COM

Belite Bio, Inc - Price Target for Depositary Receipt (BLTE) Raised by 62.05% to 188.02

People Also Watch

Frequently Asked Questions

What is Belite Bio Inc (BLTE) stock price today?

The current price of BLTE is 162.22 USD — it has decreased -1.09 % in the last trading day.

What is Belite Bio Inc (BLTE)'s business?

Belite Bio, Inc is a clinical-stage biopharmaceutical drug development company. The Company is focused on advancing novel therapeutics targeting retinal degenerative eye disease, such as Geographic Atrophy (GA), age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1), both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout. Its lead product candidate, Tinlarebant, is an oral daily treatment for STGD1 and GA patients. In STGD1, it is developing Tinlarebant as a once-a-day tablet treatment to target Retinol binding protein 4 (RBP4) by disrupting vitamin A (retinol) binding to RBP4, which leads to reduced delivery of retinol to the eye and reduced accumulation of toxic vitamin A by-products. Its product candidate also includes LBS-009, an anti-RBP4 oral therapy targeting liver disease, including NAFLD, NASH, and T2D.

What is the price predicton of BLTE Stock?

What is Belite Bio Inc (BLTE)'s revenue for the last quarter?

Belite Bio Inc revenue for the last quarter amounts to -9.74M USD, decreased -0.00 % YoY.

What is Belite Bio Inc (BLTE)'s earnings per share (EPS) for the last quarter?

Belite Bio Inc. EPS for the last quarter amounts to USD, decreased % YoY.

What changes have occurred in the market's expectations for Belite Bio Inc (BLTE)'s fundamentals?

How many employees does Belite Bio Inc (BLTE). have?

Belite Bio Inc (BLTE) has 25 emplpoyees as of January 09 2026.

What is Belite Bio Inc (BLTE) market cap?

Today BLTE has the market capitalization of 6.15B USD.